Home > Publications Database > Altered brain dynamics index levels of arousal in complete locked-in syndrome. > print

001     259235
005     20240112171440.0
024 7 _ |a 10.1038/s42003-023-05109-1
|2 doi
024 7 _ |a pmid:37474587
|2 pmid
024 7 _ |a pmc:PMC10359418
|2 pmc
024 7 _ |a altmetric:151745203
|2 altmetric
037 _ _ |a DZNE-2023-00736
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Zilio, Federico
|0 0000-0001-9220-7372
|b 0
245 _ _ |a Altered brain dynamics index levels of arousal in complete locked-in syndrome.
260 _ _ |a London
|c 2023
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1692959981_28578
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Complete locked-in syndrome (CLIS) resulting from late-stage amyotrophic lateral sclerosis (ALS) is characterised by loss of motor function and eye movements. The absence of behavioural indicators of consciousness makes the search for neuronal correlates as possible biomarkers clinically and ethically urgent. EEG-based measures of brain dynamics such as power-law exponent (PLE) and Lempel-Ziv complexity (LZC) have been shown to have explanatory power for consciousness and may provide such neuronal indices for patients with CLIS. Here, we validated PLE and LZC (calculated in a dynamic way) as benchmarks of a wide range of arousal states across different reference states of consciousness (e.g., awake, sleep stages, ketamine, sevoflurane). We show a tendency toward high PLE and low LZC, with high intra-subject fluctuations and inter-subject variability in a cohort of CLIS patients with values graded along different arousal states as in our reference data sets. In conclusion, changes in brain dynamics indicate altered arousal in CLIS. Specifically, PLE and LZC are potentially relevant biomarkers to identify or diagnose the arousal level in CLIS and to determine the optimal time point for treatment, including communication attempts.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Locked-In Syndrome
|2 MeSH
650 _ 2 |a Electroencephalography: methods
|2 MeSH
650 _ 2 |a Brain: physiology
|2 MeSH
650 _ 2 |a Wakefulness
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 7 |a Biomarkers
|2 NLM Chemicals
700 1 _ |a Gomez-Pilar, Javier
|b 1
700 1 _ |a Chaudhary, Ujwal
|b 2
700 1 _ |a Fogel, Stuart
|0 0000-0002-3227-5370
|b 3
700 1 _ |a Fomina, Tatiana
|b 4
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 5
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 6
|u dzne
700 1 _ |a Cao, Shumei
|b 7
700 1 _ |a Zhang, Jun
|b 8
700 1 _ |a Huang, Zirui
|0 0000-0002-5949-0206
|b 9
700 1 _ |a Birbaumer, Niels
|b 10
700 1 _ |a Northoff, Georg
|0 0000-0002-5236-0951
|b 11
773 _ _ |a 10.1038/s42003-023-05109-1
|g Vol. 6, no. 1, p. 757
|0 PERI:(DE-600)2919698-X
|n 1
|p 757
|t Communications biology
|v 6
|y 2023
|x 2399-3642
856 4 _ |u https://pub.dzne.de/record/259235/files/DZNE-2023-00736%20SUP.zip
856 4 _ |u https://pub.dzne.de/record/259235/files/DZNE-2023-00736.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/259235/files/DZNE-2023-00736.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:259235
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811275
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2810795
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-10-13T14:52:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-12
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-12
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:13:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:13:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:13:06Z
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b COMMUN BIOL : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2023-10-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b COMMUN BIOL : 2022
|d 2023-10-27
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
920 1 _ |0 I:(DE-2719)5000005
|k AG Schöls
|l Clinical Neurogenetics
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000005
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21